Webinar on replacing fetal bovine serum in research and testing 

The Symposium “Replacing fetal bovine serum (fbs) in research & testing” on 3 November 2020 has been changed to an online event, due to the actual increase in COVID-19 infections in Germany!
Registration is open until 25th October 2020. Please register now, since the number of participants will be limited!

You will find more information on the on-line symposium and for registration here: https://lnkd.in/d2iXS9W

In2TOX Webinar on COVID-19

Webinar organized by the  EUROTOX In Vitro and In Silico Toxicology (IN2TOX) Specialty Section, the virtual webinar "Role of in vitro and in silico methodologies in COVID-19 research" was held September 17, 2020, from 15:00 to 16:00 CET. 

The webinar was introduced by Prof. Mathieu Vinken, Chair In2TOX-EUROTOX, and consisted of the two presentations listed below.

Click on the link below to listen to each presentation.

New approach methods as door-openers for drugs and vaccines or the other way around?” by Prof. Thomas Hartung, Center for Alternatives to Animal testing, Johns Hopkins University Bloomberg School of Public Health-USA

"Studying the interaction between coronavirus spike protein and human target receptors using 3D in silico modeling: could anthraquinone compounds prevent the interaction?" by Dr. Luca Dellafiora, Department of Food and Drug, University of Parma-Italy

Webinar series: Scientific and economic benefits of animal-free antibodies

The JRC’s EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) will jointly organise a webinar on the new recommendation on non-animal-derived antibodies. 

EURL ECVAM has recently issued a Recommendation on non-animal-derived antibodies based on the opinion of EURL ECVAM’s Scientific Advisory Committee (ESAC).

The Recommendation states that animals should no longer be used for the development and production of antibodies for research, regulatory, diagnostic and therapeutic applications. It also challenges misconceptions existing in the scientific community about non-animal-derived antibodies and highlights the scientific and economic benefits of their use.

16 September, 16:00 CEST | Webinar 'Scientific and economic benefits of animal-free antibodies'

We invite you to attend this webinar where:

  • JRC scientist Joao Barroso will present a summary of the findings from the ESAC Opinion on the validity and benefits of using animal-free technology to produce affinity reagents and the subsequent EURL ECVAM Recommendation.

  • ESAC member Alison Gray will provide an overview of the scientific benefits of using animal friendly affinity reagents as replacements for animal-derived antibodies.

To attend the webinar, register here

This event is taking place in the context of a webinar series on applications and benefits of animal-free recombinant antibodies. It is co-organised by the Joint Research Centre (JRC), the US National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and the PETA International Science Consortium Ltd.

The recording is available here: https://www.piscltd.org.uk/antibody-webinars/

Webinar 1: Animal-free antibodies against diseases: Rapid response to fight Covid-19 (View recording here.)
Date: 23 July 2020

Webinar 1: Animal-free antibodies against diseases: Rapid response to fight Covid-19 (View recording here.)
Date: 23 July 2020

  • Dr. Stefan Dübel (Technische Universität Braunschweig) describes his work developing fully human antibodies against infections, such as Covid-19 and diphtheria. (View slides here.)

  • Dr. Sachdev Sidhu (Toronto Recombinant Antibody Centre) describes his successes at the Toronto Recombinant Antibody Centre, particularly related to developing non-animal antibodies against the coronavirus SARS-CoV-2. (View slides here.)

Webinar 2: Scientific and economic benefits of animal-free antibodies (View recording here.)
Date: 16 September 2020

  • Dr. Alison Gray (Afability) provides an overview of the scientific benefits of using animal friendly affinity reagents (AFAs) as replacements for animal-derived antibodies. She discusses how they are developed, how they follow the same mechanistic principles evolved by nature, and the challenges that have slowed their replacement. (View slides here.)

  • Dr. João Barroso (EURL ECVAM) shares a summary of the findings from a 2018 EURL ECVAM Scientific Advisory Committee (ESAC) meeting that reviewed the validity and benefits of using animal-free technology to produce affinity reagents and the subsequent EURL ECVAM recommendation. (View slides here.)

Webinar 3: Application of animal-free antibodies (View recording here.)
Date: 15 October 2020

  • Dr. Giulio Russo (Abcalis) discusses the replacement of animal serum-derived secondary antibodies with animal-free multiclonal antibodies. (View slides here.)

  • Dr. Charu Chandrasekera (Canadian Centre for Alternatives to Animal Methods) provides a look at her experience replacing animal-derived affinity reagents in the laboratory. (View slides here.)

Webinar 4: Accessibility of recombinant antibodies
Date: 12 November 2020
Time: 4:00–5:00 pm CEST (10:00–11:00 am EDT)
Register here: attendee.gotowebinar.com/register/8377135520110180110

  • Dr. Pierre Cosson (University of Geneva) will describe the work of the Geneva Antibody Facility and the antibody discovery and production services that they offer to the scientific community.

  • Dr. Michael Fiebig (Absolute Antibody) will provide insight on Absolute Antibody’s services sequencing existing hybridoma and ascites-derived antibodies to make them recombinantly.

JOIN THE CONVERSATION: 

  • LinkedIn

© 2023 by InVitroTox Consulting 

Proudly created using Wix.com